Jenna Najar, MD, PhD, Sahlgrenska University Hospital, Gothenburg, Sweden & Amsterdam University Medical Center, Amsterdam, Netherlands talks about her research on polygenic risk scores (PRS) in Alzheimer’s disease (AD) in relation to cognitive change. Over 900 older individuals without dementia were examined at age 70, 75, 79, and 85 years to track cognitive function. They aimed to determine if PRS for Alzheimer’s disease (AD-PRS) and genetic variants related to level of cognitive ability (COG-PRS) could predict decline in this population. Results showed that COG-PRS predicted baseline cognitive state but not change over time. Conversely, AD-PRS did not predict baseline status but did predict decline. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
